i2o Therapeutics closes $46M Series A, names Kurt Graves as CEO and acquires Intarcia’s twice-rejected diabetes asset

In a slew of company updates, i2o Therapeutics has closed a Series A raise worth $46 million from biotech investors and named Kurt Graves as …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

i2o Ther­a­peu­tics clos­es $46M Se­ries A, names Kurt Graves as CEO and ac­quires Intar­cia’s twice-re­ject­ed di­a­betes as­set